Literature DB >> 32611757

Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.

Ashlie Thomas1, Devina J Thiono1, Stephan T Kudlacek2, John Forsberg3, Lakshmanane Premkumar1, Shaomin Tian1, Brian Kuhlman2, Aravinda M de Silva1, Stefan W Metz4.   

Abstract

Dengue virus (DENV) is responsible for the most prevalent and significant arthropod-borne viral infection of humans. The leading DENV vaccines are based on tetravalent live-attenuated virus platforms. In practice, it has been challenging to induce balanced and effective responses to each of the four DENV serotypes because of differences in the replication efficiency and immunogenicity of individual vaccine components. Unlike live vaccines, tetravalent DENV envelope (E) protein subunit vaccines are likely to stimulate balanced immune responses, because immunogenicity is replication independent. However, E protein subunit vaccines have historically performed poorly, in part because the antigens utilized were mainly monomers that did not display quaternary-structure epitopes found on E dimers and higher-order structures that form the viral envelope. In this study, we compared the immunogenicity of DENV2 E homodimers and DENV2 E monomers. The stabilized DENV2 homodimers, but not monomers, were efficiently recognized by virus-specific and flavivirus cross-reactive potently neutralizing antibodies that have been mapped to quaternary-structure epitopes displayed on the viral surface. In mice, the dimers stimulated 3-fold-higher levels of virus-specific neutralizing IgG that recognized epitopes different from those recognized by lower-level neutralizing antibodies induced by monomers. The dimer induced a stronger E domain I (EDI)- and EDII-targeted response, while the monomer antigens stimulated an EDIII epitope response and induced fusion loop epitope antibodies that are known to facilitate antibody-dependent enhancement (ADE). This study shows that DENV E subunit antigens that have been designed to mimic the structural organization of the viral surface are better vaccine antigens than E protein monomers.IMPORTANCE Dengue virus vaccine development is particularly challenging because vaccines have to provide protection against four different dengue virus stereotypes. The leading dengue virus vaccine candidates in clinical testing are all based on live-virus vaccine platforms and struggle to induce balanced immunity. Envelope subunit antigens have the potential to overcome these limitations but have historically performed poorly as vaccine antigens, because the versions tested previously were presented as monomers and not in their natural dimer configuration. This study shows that the authentic presentation of DENV2 E-based subunits has a strong impact on antibody responses, underscoring the importance of mimicking the complex protein structures that are found on DENV particle surfaces when designing subunit vaccines.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  antibody focus; dengue virus; envelope protein; homodimers; neutralizing antibodies; subunit vaccine

Mesh:

Substances:

Year:  2020        PMID: 32611757      PMCID: PMC7459570          DOI: 10.1128/JVI.00745-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice.

Authors:  E P Kelly; J J Greene; A D King; B L Innis
Journal:  Vaccine       Date:  2000-05-22       Impact factor: 3.641

2.  Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly.

Authors:  Melissanne de Wispelaere; Priscilla L Yang
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering.

Authors:  Tewodros Mamo; Gregory A Poland
Journal:  Vaccine       Date:  2012-10-19       Impact factor: 3.641

Review 4.  The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.

Authors:  Beth-Ann G Coller; David E Clements; Andrew J Bett; Sangeetha L Sagar; Jan H Ter Meulen
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

5.  Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris.

Authors:  María G Guzmán; Rayner Rodríguez; Rosmari Rodríguez; Lisset Hermida; Mayling Alvarez; Laura Lazo; Mayra Muné; Delfina Rosario; Katia Valdés; Susana Vázquez; Rafael Martinez; Teresita Serrano; Jorge Paez; Raúl Espinosa; Tania Pumariega; Gerardo Guillén
Journal:  Am J Trop Med Hyg       Date:  2003-08       Impact factor: 2.345

6.  Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation.

Authors:  Stéphane Bressanelli; Karin Stiasny; Steven L Allison; Enrico A Stura; Stéphane Duquerroy; Julien Lescar; Franz X Heinz; Félix A Rey
Journal:  EMBO J       Date:  2004-02-12       Impact factor: 11.598

7.  Recognition determinants of broadly neutralizing human antibodies against dengue viruses.

Authors:  Alexander Rouvinski; Pablo Guardado-Calvo; Giovanna Barba-Spaeth; Stéphane Duquerroy; Marie-Christine Vaney; Carlos M Kikuti; M Erika Navarro Sanchez; Wanwisa Dejnirattisai; Wiyada Wongwiwat; Ahmed Haouz; Christine Girard-Blanc; Stéphane Petres; William E Shepard; Philippe Desprès; Fernando Arenzana-Seisdedos; Philippe Dussart; Juthathip Mongkolsapaya; Gavin R Screaton; Félix A Rey
Journal:  Nature       Date:  2015-01-12       Impact factor: 49.962

8.  The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Authors:  Scott A Smith; A Ruklanthi de Alwis; Nurgun Kose; Eva Harris; Kristie D Ibarra; Kristen M Kahle; Jennifer M Pfaff; Xiaoxiao Xiang; Benjamin J Doranz; Aravinda M de Silva; S Kyle Austin; Soila Sukupolvi-Petty; Michael S Diamond; James E Crowe
Journal:  mBio       Date:  2013-11-19       Impact factor: 7.867

9.  Oligomeric state of the ZIKV E protein defines protective immune responses.

Authors:  Stefan W Metz; Ashlie Thomas; Alex Brackbill; John Forsberg; Michael J Miley; Cesar A Lopez; Helen M Lazear; Shaomin Tian; Aravinda M de Silva
Journal:  Nat Commun       Date:  2019-10-10       Impact factor: 14.919

10.  The global distribution and burden of dengue.

Authors:  Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962

View more
  2 in total

1.  A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice.

Authors:  Lihong He; Wenqiang Sun; Limin Yang; Wenjun Liu; Jing Li
Journal:  Virol Sin       Date:  2022-07-12       Impact factor: 6.947

Review 2.  Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.

Authors:  Rahul Shukla; Viswanathan Ramasamy; Rajgokul K Shanmugam; Richa Ahuja; Navin Khanna
Journal:  Front Cell Infect Microbiol       Date:  2020-10-22       Impact factor: 5.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.